Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Tufts researchers uncover immune cell link to doxorubicin-induced heart damage

There's still much to learn about how doxorubicin, a 50-year-old chemotherapy drug, causes its most concerning side effects.

17 Jul 2024

NYU Langone Health earns No. 1 spot in neurology and neurosurgery for the third straight year

NYU Langone Health has reaffirmed its position as the nation's top hospital for neurology and neurosurgery, securing the No. 1 ranking for the third straight year in U.S. News & World Report's annual assessment of leading hospitals.

16 Jul 2024

40% of US cancer cases linked to lifestyle choices

Nearly 40% of cancer cases and 44% of cancer deaths in 2019 were due to modifiable risk factors, with cigarette smoking as the leading cause. This study highlights the potential to significantly reduce cancer burden through lifestyle changes.

14 Jul 2024

CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma

CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced improvement with chemotherapy treatments.

11 Jul 2024

Novel Co-STAR cells show promise in targeting and eradicating cancer

Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and fight cancer.

11 Jul 2024

Scientists discover a molecular defect that promotes pathologic immune response in lupus

Northwestern Medicine and Brigham and Women's Hospital scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect may potentially reverse the disease.

10 Jul 2024

Hesse's LOEWE program supports cutting-edge CAR-T cell therapy research

LOEWE, the federal state of Hesse's research promotion program for the development of scientific and economic excellence, is providing €4.8 million in funding for a new research network spearheaded by Goethe University.

28 Jun 2024

Research finds stem-like T cells are associated with pathogenesis in ulcerative colitis

Researchers investigated whether stem-like T lymphocytes are involved in ulcerative colitis pathogenesis.

21 Jun 2024

Combining JAK inhibitors with checkpoint inhibitors improves cancer immunotherapy response

Because not all cancer patients respond to a leading type of cancer immunotherapy drug, known as an immune checkpoint inhibitor, scientists explored whether adding janus kinase (JAK) inhibitors – drugs that treat chronic inflammation – could help.

20 Jun 2024

JAK inhibitor ruxolitinib enhances immunotherapy in Hodgkin lymphoma patients

Checkpoint inhibitor therapies can be thought of as the molecular "brake release" for the immune system.

20 Jun 2024

Non-chemotherapy treatment regimen achieves full remission in aggressive B-cell lymphoma

Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments.

19 Jun 2024

Rapid test detects brain cancer mutations in cerebrospinal fluid

A test that looks for genetic hallmarks of brain cancers in samples of cerebrospinal fluid can decrease the time to diagnosis and eliminate the need for invasive brain biopsies for some patients.

17 Jun 2024

Case study sheds light on CAR-T therapy-related secondary cancers

A new detailed analysis of a patient's second cancer after receiving CAR-T therapy for the initial cancer provides rare but important insights intended to offer helpful guidance for oncologists and pathologists about the clinical presentation and pathologic features involved in a CAR-T related second cancer.

13 Jun 2024

New armored CAR T cell therapy boosts response in Relapsed non-Hodgkin lymphoma patients

While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin lymphoma (NHL), many patients who receive CAR T cell therapy do not experience a long-term remission.

13 Jun 2024

Targeting basophils to revitalize cytotoxic T-cells in tumor microenvironment

The ecosystem that surrounds a tumor, also known as the tumor microenvironment, includes immune cells, tissues, blood vessels and other cells that interact with each other and with the tumor.

13 Jun 2024

MEK inhibitor trametinib shows potential in pediatric JMML treatment

The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II clinical trial, with seven of 10 patients alive after a median of two years.

13 Jun 2024

Stanford study finds low risk of secondary blood cancers after CAR-T cell therapy

A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy - a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable blood cancers - is low, despite a Food and Drug Administration warning.

12 Jun 2024

Lymphoma News and Research

Further Reading

Tufts researchers uncover immune cell link to doxorubicin-induced heart damage

NYU Langone Health earns No. 1 spot in neurology and neurosurgery for the third straight year

40% of US cancer cases linked to lifestyle choices

CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma

Novel Co-STAR cells show promise in targeting and eradicating cancer

Scientists discover a molecular defect that promotes pathologic immune response in lupus

Hesse's LOEWE program supports cutting-edge CAR-T cell therapy research

Research finds stem-like T cells are associated with pathogenesis in ulcerative colitis

Combining JAK inhibitors with checkpoint inhibitors improves cancer immunotherapy response

JAK inhibitor ruxolitinib enhances immunotherapy in Hodgkin lymphoma patients

Non-chemotherapy treatment regimen achieves full remission in aggressive B-cell lymphoma

Rapid test detects brain cancer mutations in cerebrospinal fluid

Case study sheds light on CAR-T therapy-related secondary cancers

New armored CAR T cell therapy boosts response in Relapsed non-Hodgkin lymphoma patients

Targeting basophils to revitalize cytotoxic T-cells in tumor microenvironment

MEK inhibitor trametinib shows potential in pediatric JMML treatment

Stanford study finds low risk of secondary blood cancers after CAR-T cell therapy

Enhancing CAR-T cell therapy with biodegradable scaffolds

Revolutionary AI tool detects multiple cancers in whole-body PET/CT scans

Blocking CDK7 protein could prevent heart damage associated with cancer treatment

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News